HCA Healthcare (HCA) Competitors

$322.86
+0.15 (+0.05%)
(As of 05/17/2024 ET)

HCA vs. GILD, BMY, ZTS, GSK, MCK, CI, BDX, BSX, REGN, and VRTX

Should you be buying HCA Healthcare stock or one of its competitors? The main competitors of HCA Healthcare include Gilead Sciences (GILD), Bristol-Myers Squibb (BMY), Zoetis (ZTS), GSK (GSK), McKesson (MCK), The Cigna Group (CI), Becton, Dickinson and Company (BDX), Boston Scientific (BSX), Regeneron Pharmaceuticals (REGN), and Vertex Pharmaceuticals (VRTX). These companies are all part of the "medical" sector.

HCA Healthcare vs.

Gilead Sciences (NASDAQ:GILD) and HCA Healthcare (NYSE:HCA) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, valuation, community ranking, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership.

HCA Healthcare has a net margin of 8.20% compared to HCA Healthcare's net margin of 1.76%. Gilead Sciences' return on equity of 674.49% beat HCA Healthcare's return on equity.

Company Net Margins Return on Equity Return on Assets
Gilead Sciences1.76% 24.34% 8.36%
HCA Healthcare 8.20%674.49%9.59%

Gilead Sciences has a beta of 0.22, suggesting that its share price is 78% less volatile than the S&P 500. Comparatively, HCA Healthcare has a beta of 1.66, suggesting that its share price is 66% more volatile than the S&P 500.

Gilead Sciences has higher earnings, but lower revenue than HCA Healthcare. HCA Healthcare is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gilead Sciences$27.12B3.11$5.67B$0.36188.11
HCA Healthcare$64.97B1.30$5.24B$20.0616.09

Gilead Sciences currently has a consensus target price of $83.69, indicating a potential upside of 23.58%. HCA Healthcare has a consensus target price of $317.00, indicating a potential downside of 1.82%. Given HCA Healthcare's higher possible upside, equities analysts plainly believe Gilead Sciences is more favorable than HCA Healthcare.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gilead Sciences
0 Sell rating(s)
11 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.35
HCA Healthcare
0 Sell rating(s)
4 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.75

83.7% of Gilead Sciences shares are held by institutional investors. Comparatively, 62.7% of HCA Healthcare shares are held by institutional investors. 0.2% of Gilead Sciences shares are held by insiders. Comparatively, 1.6% of HCA Healthcare shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Gilead Sciences received 1251 more outperform votes than HCA Healthcare when rated by MarketBeat users. Likewise, 77.37% of users gave Gilead Sciences an outperform vote while only 77.33% of users gave HCA Healthcare an outperform vote.

CompanyUnderperformOutperform
Gilead SciencesOutperform Votes
2448
77.37%
Underperform Votes
716
22.63%
HCA HealthcareOutperform Votes
1197
77.33%
Underperform Votes
351
22.67%

In the previous week, HCA Healthcare had 8 more articles in the media than Gilead Sciences. MarketBeat recorded 23 mentions for HCA Healthcare and 15 mentions for Gilead Sciences. HCA Healthcare's average media sentiment score of 0.55 beat Gilead Sciences' score of 0.27 indicating that Gilead Sciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Gilead Sciences
7 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
HCA Healthcare
11 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Gilead Sciences pays an annual dividend of $3.08 per share and has a dividend yield of 4.5%. HCA Healthcare pays an annual dividend of $2.64 per share and has a dividend yield of 0.8%. Gilead Sciences pays out 855.6% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. HCA Healthcare pays out 13.2% of its earnings in the form of a dividend. Gilead Sciences has raised its dividend for 9 consecutive years and HCA Healthcare has raised its dividend for 5 consecutive years. Gilead Sciences is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Summary

HCA Healthcare beats Gilead Sciences on 11 of the 21 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HCA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HCA vs. The Competition

MetricHCA HealthcareGeneral medical & surgical hospitals IndustryMedical SectorNYSE Exchange
Market Cap$84.56B$16.15B$5.11B$18.05B
Dividend Yield0.81%0.63%43.85%3.43%
P/E Ratio16.0911.15148.0023.97
Price / Sales1.300.682,361.3710.29
Price / Cash10.4612.1736.6420.14
Price / Book66.5714.465.766.01
Net Income$5.24B$917.90M$104.93M$966.25M
7 Day Performance-1.16%0.58%1.87%1.87%
1 Month Performance8.71%13.43%4.76%7.16%
1 Year Performance15.55%8.07%7.73%21.68%

HCA Healthcare Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GILD
Gilead Sciences
4.8468 of 5 stars
$67.65
+0.2%
$83.69
+23.7%
-14.1%$84.28B$27.45B187.9218,000
BMY
Bristol-Myers Squibb
4.9976 of 5 stars
$44.73
-0.7%
$60.00
+34.1%
-33.8%$90.67B$45.01B-14.4334,100
ZTS
Zoetis
4.6692 of 5 stars
$168.87
+0.6%
$211.75
+25.4%
-2.7%$77.06B$8.54B32.5414,100
GSK
GSK
1.9529 of 5 stars
$45.66
+1.1%
N/A+24.5%$94.63B$30.74B16.5470,200News Coverage
MCK
McKesson
4.6641 of 5 stars
$551.58
-0.5%
$571.47
+3.6%
+40.8%$71.70B$308.95B24.6551,000Insider Selling
CI
The Cigna Group
4.691 of 5 stars
$346.17
-0.9%
$366.14
+5.8%
+28.7%$98.34B$195.27B28.4272,500Insider Selling
Short Interest ↓
BDX
Becton, Dickinson and Company
4.9161 of 5 stars
$235.00
-0.8%
$281.40
+19.7%
-6.0%$67.92B$19.37B51.7673,000Insider Selling
Short Interest ↓
News Coverage
BSX
Boston Scientific
4.3204 of 5 stars
$73.47
+0.9%
$75.09
+2.2%
+39.8%$107.79B$14.24B61.7448,000Analyst Forecast
Short Interest ↑
REGN
Regeneron Pharmaceuticals
4.0517 of 5 stars
$984.64
+0.8%
$981.71
-0.3%
+31.0%$108.50B$13.12B29.0913,450Analyst Forecast
Insider Selling
VRTX
Vertex Pharmaceuticals
4.1451 of 5 stars
$428.59
-0.3%
$432.18
+0.8%
+30.5%$110.60B$9.87B27.815,400

Related Companies and Tools

This page (NYSE:HCA) was last updated on 5/18/2024 by MarketBeat.com Staff

From Our Partners